CRISPR/Cas9-mediated silencing of AP-1 subunits in HUtSMCs demonstrates that loss of AP-1 can indeed cause the large-scale gene expression and enhancer acetylation changes seen in leiomyoma tissue samples. This evidence concerns the gene FOSB and leiomyoma.